Onconova Therapeutics, Inc.·4

Jun 17, 7:46 PM ET

Gelder Mark S. MD 4

4 · Onconova Therapeutics, Inc. · Filed Jun 17, 2021

Insider Transaction Report

Form 4
Period: 2021-06-14
Gelder Mark S. MD
Chief Medical Officer
Transactions
  • Award

    Stock Option (right to purchase)

    2021-06-14+20,00020,000 total
    Exercise: $7.56Exp: 2031-06-14Common Stock (20,000 underlying)
Footnotes (1)
  • [F1]Theses options vest over 4 years, 25% on the first anniversary of the grant and thereafter in 36 equal monthly installments over the next 3 years.

Documents

1 file
  • 4
    edgar.xmlPrimary

    FORM 4 -